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The α-arrestin ARRDC3 mediates ALIX 
ubiquitination and G protein–coupled receptor 
lysosomal sorting
Michael R. Dores, Huilan Lin, Neil J. Grimsey, Francisco Mendez, and JoAnn Trejo
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093
ABSTRACT The sorting of G protein–coupled receptors (GPCRs) to lysosomes is critical for 
proper signaling and cellular responses. We previously showed that the adaptor protein ALIX 
regulates lysosomal degradation of protease-activated receptor-1 (PAR1), a GPCR for throm-
bin, independent of ubiquitin-binding ESCRTs and receptor ubiquitination. However, the 
mechanisms that regulate ALIX function during PAR1 lysosomal sorting are not known. Here 
we show that the mammalian α-arrestin arrestin domain–containing protein-3 (ARRDC3) reg-
ulates ALIX function in GPCR sorting via ubiquitination. ARRDC3 colocalizes with ALIX and is 
required for PAR1 sorting at late endosomes and degradation. Depletion of ARRDC3 by small 
interfering RNA disrupts ALIX interaction with activated PAR1 and the CHMP4B ESCRT-III 
subunit, suggesting that ARRDC3 regulates ALIX activity. We found that ARRDC3 is required 
for ALIX ubiquitination induced by activation of PAR1. A screen of nine mammalian NEDD4-
family E3 ubiquitin ligases revealed a critical role for WWP2. WWP2 interacts with ARRDC3 
and not ALIX. Depletion of WWP2 inhibited ALIX ubiquitination and blocked ALIX interaction 
with activated PAR1 and CHMP4B. These findings demonstrate a new role for the α-arrestin 
ARRDC3 and the E3 ubiquitin ligase WWP2 in regulation of ALIX ubiquitination and lyso-
somal sorting of GPCRs.
INTRODUCTION
G protein–coupled receptors (GPCRs) make up the largest family of 
mammalian signaling receptors and major pharmaceutical targets 
for the treatment of many human diseases, including cancer, cardio-
vascular disease, and chronic inflammatory disorders (Mason et al., 
2012; O’Hayre et al., 2014). Lysosomal sorting and degradation of 
GPCRs is critical for proper control of signaling and cellular re-
sponses (Marchese et al., 2008; Marchese and Trejo, 2012). Multiple 
pathways exist to sort mammalian GPCRs to lysosomes for degrada-
tion. The best-characterized pathway is an evolutionarily conserved 
process that requires receptor ubiquitination and the endosomal 
sorting complexes required for transport (ESCRT) machinery. Ubiq-
uitin-binding proteins within the ESCRT-0 and ESCRT-I complexes 
interact with GPCRs posttranslationally modified with ubiquitin to 
facilitate the sorting of receptors at the early endosome. GPCRs are 
then packaged into intraluminal vesicles by the ESCRT-II and III com-
plexes, forming multivesicular endosomes (MVEs) that then fuse 
with lysosomes. We previously identified an alternative pathway for 
sorting GPCRs into the MVE that is dependent on the adaptor pro-
tein ALG-interacting protein X (ALIX) and does not require direct 
GPCR ubiquitination and ESCRT-0 and -I complexes (Gullapalli 
et al., 2006; Wolfe et al., 2007; Dores et al., 2012a). ALIX regulates 
the degradation of protease-activated receptor-1 (PAR1), a GPCR 
for thrombin (Soh and Trejo, 2011), by coupling PAR1 to the ESCRT-
III complex subunit CHMP4 (Dores et al., 2012a). However, the 
mechanisms that regulate ALIX-dependent GPCR sorting at multi-
vesicular endosomes remain poorly understood.
ALIX has been shown to interact with the mammalian α-arrestins 
during viral budding at the plasma membrane (Rauch and Martin-
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for the packaging of PAR1 into intraluminal vesicles of multivesicular 
endosomes.
RESULTS
PAR1 interacts with ARRDC3
The mechanisms that regulate ALIX function in GPCR lysosomal 
sorting are not known. We hypothesize that ALIX binding partners 
such as ARRDC3 may serve an important function in PAR1 endo-
somal/lysosomal sorting. To characterize the function of ARRDC3 in 
PAR1 trafficking, we used bioluminescence resonance energy trans-
fer (BRET) to test whether ARRDC3 interacts with PAR1 in living cells. 
COS7 cells coexpressing a constant amount of ARRDC3 fused to 
Renilla reniformis luciferase (Rluc) and increasing amounts of PAR1 
fused to yellow fluorescent protein (YFP) exhibited changes in net 
BRET. The net BRET signal increased and saturated as the ratio of 
PAR1 to ARRDC3 was increased, indicating that ARRDC3 and PAR1 
specifically interact (Figure 1A). In contrast, cells expressing ARRDC3 
Rluc and the related thrombin receptor PAR4 did not exhibit signifi-
cant changes in net BRET, and the BRET signal failed to saturate, 
indicating a nonspecific interaction (Figure 1A). These data suggest 
that ARRDC3 specifically interacts with PAR1 in comparison to other 
PARs. A fixed ratio of PAR1-YFP to ARRDC3-Rluc was then used to 
examine whether stimulation of PAR1 with thrombin affected the 
interaction. Under control conditions, PAR1/ARRDC3 exhibited a 
substantial BRET signal compared with PAR4/ARRDC3, which was 
used as a negative control (Figure 1B). Incubation with thrombin did 
not significantly alter the BRET signal between ARRDC3 and PAR1 
or PAR4 (Figure 1B). These findings suggest that ARRDC3 associ-
ates with PAR1 basally and that activation of PAR1 does not appear 
to enhance or disrupt PAR1 and ARRDC3 interaction.
PAR1 resides primarily at the plasma membrane and, after acti-
vation, is rapidly internalized and trafficked to early and then late 
endosomes/lysosomes before degradation (Dores et al., 2012a). 
Because PAR1 and ARRDC3 remain associated after agonist stimu-
lation (Figure 1B), we examined whether activated PAR1-ARRDC3 
colocalizes with ALIX on endosomes, using immunofluorescence 
confocal microscopy. HeLa cells expressing FLAG-PAR1 were co-
transfected with hemagglutinin (HA)-ARRDC3 and ALIX fused to 
split-YFP. ALIX primarily localizes to the cytoplasm and associates 
with membranes upon dimerization (Pires et al., 2009; Bissig et al., 
2013). Dimerized ALIX can be visualized using split-YFP in which ei-
ther the N- or C-domain of YFP protein is fused to ALIX lacking its 
C-terminal proline-rich domain (Bissig et al., 2013). On dimerization, 
the YFP N- and C-domains interact and fluoresce (Pires et al., 2009; 
Bissig et al., 2013). The surface cohort of PAR1 was labeled with anti-
FLAG antibody at 4°C. In the absence of agonist, ARRDC3 and 
PAR1 appear to partially colocalize at the plasma membrane, as as-
sessed by confocal microscopy (Figure 1C) and verified by Pearson’s 
r, r = 0.55. In unstimulated cells, ARRDC3 also colocalizes with ALIX 
in early and late endosomes (Supplemental Figure S1, A and B). In 
contrast, surface-labeled PAR1 and ALIX are not colocalized in un-
treated cells (Figure 1C). We next examined whether activation of 
PAR1 affected colocalization with ALIX and ARRDC3, using the ago-
nist peptide SFLLRN, since thrombin cleaves off the N-terminal 
FLAG epitope of PAR1 (Vu et al., 1991). After 20 min of agonist 
stimulation, PAR1 sorted to ARRDC3- and ALIX-positive internal 
punctae (Figure 1C). In addition, the extent of PAR1 colocalization 
with ARRDC3 and ALIX was increased, as reflected by r = 0.78 and 
0.67, respectively. Of interest, agonist stimulation did not signifi-
cantly change the extent of ARRDC3 colocalization with ALIX in 
early and late endosomes (Supplemental Figure S1C), suggesting 
that membrane trafficking of PAR1 does not significantly alter the 
arrestin domain–containing proteins (ARRDCs) and thioredoxin-in-
teracting protein (TXNIP) that share similar domain homology with 
the mammalian β-arrestins (Alvarez, 2008). ALIX binds to the C-ter-
minal region of TXNIP and ARRDCs 1–4 (Rauch and Martin-Serrano, 
2011). These α-arrestins also harbor PPXY motifs within the C-termi-
nal region that are required for interaction with neural precursor 
cell–expressed, developmentally down-regulated protein 4 
(NEDD4)–family E3 ubiquitin ligases (Nabhan et al., 2010; Rauch 
and Martin-Serrano, 2011; Shea et al., 2012). ARRDC1 forms a com-
plex with NEDD4.1 and ALIX at the plasma membrane, facilitating 
the assembly of the ALIX-dependent ESCRT complex during the 
late stages of viral budding (Rauch and Martin-Serrano, 2011). In 
addition, NEDD4.1 mediates ubiquitination of ALIX during viral 
budding, suggesting that ALIX function may be regulated by ubiq-
uitination (Sette et al., 2010). ALIX harbors a ubiquitin-binding 
domain within the central V-domain (Keren-Kaplan et al., 2013; 
Pashkova et al., 2013), and ubiquitination of ALIX may regulate its 
dimerization. Of interest, ALIX ubiquitin-binding is required for di-
merization in vitro (Keren-Kaplan et al., 2013). Dimerization of ALIX 
facilitates the recruitment of the ESCRT-III complex (Pires et al., 
2009), and dimerized ALIX localizes to internal endosomal punctae 
(Bissig et al., 2013). These findings suggest that ARRDCs may medi-
ate E3 ligase recruitment to ALIX and may regulate ALIX ubiquitina-
tion and function at endosomes.
ARRDCs may also regulate GPCR sorting at endosomes. The β2-
adrenergic receptor (β2-AR) is ubiquitinated after agonist stimula-
tion, and receptor ubiquitination appears to facilitate lysosomal 
degradation (Shenoy et al., 2008). ARRDC1 and ARRDC3 colocalize 
and associate with agonist-activated β2-AR at endosomes (Nabhan 
et al., 2010; Han et al., 2012; Shea et al., 2012). Agonist-stimulated 
β2-AR ubiquitination was inhibited by small interfering RNA (siRNA)–
mediated depletion of ARRDC3 and overexpression of an ARRDC3 
mutant lacking functional PPXY motifs (Nabhan et al., 2010; Shea 
et al., 2012). These data suggest that ARRDC3 recruits NEDD4.1 to 
ubiquitinate β2-AR. However, further studies demonstrated that β-
arrestins function as the primary adaptors to recruit NEDD4.1 to fa-
cilitate ubiquitination of β2-AR after agonist stimulation (Han et al., 
2012), whereas ARRDC3 is recruited secondarily to the β2-AR/
NEDD4.1 complex at endosomes and facilitates trafficking to a sub-
population of early endosomes (Han et al., 2012). Of interest, 
ARRDC3 binds to β-arrestins and hepatocyte growth factor–regu-
lated tyrosine kinase substrate (HRS), a component of the ESCRT-0 
complex that binds ubiquitinated receptors at early endosomes 
(Shea et al., 2012). Thus ARRDC3 may regulate the stability and re-
cruitment of the protein complexes that mediate β2-AR sorting at 
endosomes. However, further work is required to identify the exact 
function of α-arrestins in the endosomal/lysosomal sorting of GPCRs 
that require ubiquitination for degradation like the β2-AR.
In contrast to the β2-AR, the role of ARRDCs in the regulation of 
ALIX-dependent GPCR degradation has not been examined. Here 
we report that the α-arrestin ARRDC3 mediates degradation of acti-
vated PAR1 by regulating receptor sorting into the lumen of multi-
vesicular endosomes. PAR1, ARRDC3, and ALIX colocalize on endo-
somes, and ARRDC3 is required for ALIX interaction with PAR1 and 
the ESCRT-III subunit CHMP4B. Moreover, activation of PAR1 in-
creases ALIX ubiquitination that is dependent on ARRDC3 and WW 
domain–containing E3 ubiquitin protein ligase 2 (WWP2). In addi-
tion, the depletion of WWP2 not only blocks ALIX ubiquitination, 
but it also inhibits the capacity of ALIX to bind PAR1 and CHMP4B, 
which is essential for PAR1 degradation. These findings demon-
strate that ARRDC3 regulates ALIX during GPCR lysosomal sorting 
and suggest that WWP2-dependent ALIX ubiquitination is required 
4662 | M. R. Dores et al. Molecular Biology of the Cell
cells depleted of endogenous ARRDC3 (Supplemental Figure S2B). 
Activated PAR1 was degraded, reflected by ∼50% loss in receptor 
protein, in cells transfected with nonspecific siRNA and plasmid 
control (pcDNA) vector (Figure 2B, lanes 1 and 2). However, in cells 
transfected with ARRDC3 siRNA and pcDNA vector, only ∼15% of 
activated PAR1 is degraded (Figure 2B, lanes 3 and 4). Of impor-
tance, agonist-stimulated PAR1 degradation was restored to control 
levels in cells transfected with ARRDC3 siRNA and siRNA-resistant 
ARRDC3 (Figure 2B, lanes 5 and 6). These results indicate that 
ARRDC3 expression is both necessary and sufficient for agonist-
promoted PAR1 degradation.
Similar to other GPCRs, PAR1 is ubiquitinated (Wolfe et al., 2007; 
Chen et al., 2011). However, ubiquitination of PAR1 is not required 
for lysosomal degradation (Wolfe et al., 2007). In addition, a ubiqui-
tin-deficient PAR1 “0K” mutant lacking all intracellular lysine (K) resi-
dues is sorted into intraluminal vesicles of multivesicular endosomes 
and requires ALIX for degradation (Dores et al., 2012a). To test 
whether ubiquitin-independent PAR1 degradation also requires 
ARRDC3, we transfected HeLa cells expressing the PAR1 0K mutant 
distribution of ARRDC3 at endosomes. These data demonstrate 
that activated PAR1 internalizes from the cell surface and colocalizes 
with both ARRDC3 and dimerized ALIX on endosomes.
ARRDC3 is required for PAR1 degradation
Next we assessed whether ARRDC3 is required for the lysosomal 
degradation of PAR1. Transfection of HeLa cells expressing PAR1 
with ARRDC3-specific siRNAs caused a significant reduction in the 
expression of endogenous ARRDC3 compared with cells trans-
fected with nonspecific siRNAs (Supplemental Figure S2A). In non-
specific siRNA control–transfected cells, agonist caused a significant 
∼55% loss of PAR1 protein (Figure 2A, lanes 1 and 2). In contrast, the 
extent of PAR1 degradation was markedly reduced in cells depleted 
of endogenous ARRDC3. Only ∼15% of PAR1 was degraded after 
60 min of agonist incubation (Figure 2A, lanes 5 and 6). As expected, 
cells transfected with ALIX siRNAs also blocked agonist-driven PAR1 
degradation to a similar extent (Figure 2A, lanes 3–6; Dores et al., 
2012a). To confirm that ARRDC3 is specifically required for PAR1 
degradation, we expressed an siRNA-resistant mutant of ARRDC3 in 
FIGURE 1: ARRDC3 interacts and colocalizes with PAR1. (A) COS7 cells were transfected with ARRDC3-Rluc and an 
increasing amount of PAR1-YFP or PAR4-YFP. Net BRET was calculated from wells and plotted against the ratio of YFP 
to Rluc signal. (B) COS7 cells expressing ARRDC3-Rluc and PAR1-YFP or PAR4-YFP were stimulated with 10 nM 
thrombin or treated with buffer, and the BRET ratio was calculated. Results are representative of three independent 
experiments. (C) HeLa cells stably expressing FLAG-PAR1 (blue) were transfected with ALIX fused to the N-terminal 
domain of YFP (YFPn) or C-terminal domain of YFP (YFPc) together with HA-ARRDC3 (red). Cells were stimulated with 
100 μM SFLLRN and then fixed, permeabilized, and processed for immunofluorescence microscopy. Scale bars, 10 μM. 
The colocalization between PAR1, ARRDC3, and ALIX after agonist treatment was quantified by calculating Pearson’s r 
of unstimulated and stimulated cells. The data represent the mean ± SD (n = 6) and were compared using Student’s 
t test (**p < 0.01; ***p < 0.001).
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that ARRDC3 regulates ubiquitin-independent lysosomal sorting of 
receptors. We next examined whether ARRDC3 is required for the 
lysosomal sorting of ubiquitinated receptors that traffic through the 
classic ESCRT pathway. The loss of ARRDC3 failed to affect agonist-
promoted degradation of the epidermal growth factor receptor 
(EGFR; Figure 3B), a receptor tyrosine kinase that sorts through a 
ubiquitin and ESCRT pathway before lysosomal degradation (Duan 
et al., 2003). In addition, ARRDC3 depletion did not inhibit agonist-
induced degradation of PAR2 (Figure 3C), a protease-activated 
GPCR that requires receptor ubiquitination and ESCRT-0 complexes 
for lysosomal degradation (Hasdemir et al., 2009). The extent of 
siRNA-mediated ARRDC3 depletion was comparable under all con-
ditions (Supplemental Figure S3). These results indicate that 
ARRDC3 is required for ubiquitin-independent lysosomal degrada-
tion of PAR1 and suggest that ARRDC3 is not required for the deg-
radation of ubiquitinated receptors that traffic through the canonical 
ESCRT pathway.
ARRDC3 mediates PAR1 sorting into late/multivesicular 
endosomes
ARRDC3 colocalizes with PAR1 at the plasma membrane and at en-
dosomes (Figure 1C) and is required for PAR1 degradation (Figure 2). 
However, it is unclear how ARRDC3 mediates PAR1 endocytic sort-
ing. We first tested whether ARRDC3 depletion inhibits PAR1 inter-
nalization, using cell-surface enzyme-linked immunosorbent assay 
(ELISA). HeLa cells expressing FLAG-PAR1 were surface labeled with 
anti-FLAG antibody and then stimulated with agonist to induce in-
ternalization. Cells were then fixed, and the amount of anti-FLAG 
antibody remaining on the cell surface was quantified. Agonist stim-
ulation induced ∼50% loss of PAR1 from the cell surface in nonspe-
cific siRNA–transfected cells compared with untreated control cells 
(Figure 4A). The extent of agonist-induced internalization of PAR1 
was similar in cells depleted of either ALIX or ARRDC3 expression 
(Figure 4A), suggesting that ARRDC3 is not required for activated 
PAR1 internalization. After internalization, PAR1 is sorted from early 
endosomes to late endosomes/multivesicular endosomes before 
degradation (Dores et al., 2012a). Confocal immunofluorescence 
microscopy was used to examine whether ARRDC3 is required for 
PAR1 sorting at early endosomes. HeLa cells expressing FLAG-PAR1 
were prelabeled with anti-FLAG antibody and then stimulated with 
agonist for the indicated times. Cells were fixed, permeabilized, and 
immunostained for the early endosomal antigen 1 (EEA1), a mem-
brane-associated marker for the early endosome. In cells treated 
with either nonspecific or ARRDC3 siRNA, PAR1 exhibited marked 
internalization and colocalization with EEA1 after 10 min of agonist 
stimulation, which was verified by Pearson’s r (nonspecific siRNA, r = 
0.48; ARRDC3 siRNA, r = 0.5; Figure 4B). After 20 min of agonist 
stimulation, PAR1 appeared to sort away from EEA1-positive early 
endosomes in both control and ARRDC3-depleted cells, as demon-
strated by a significant reduction to r = 0.2 (Figure 4B). These find-
ings indicate that ARRDC3 is not required for PAR1 sorting at the 
early endosome.
Next we examined whether ARRDC3 is required for PAR1 sorting 
into the lumen of multivesicular endosomes. To visualize PAR1 incor-
poration into the lumen of late endosomes, we transfected FLAG-
PAR1–expressing cells with a green fluorescent protein (GFP)–
tagged, constitutively active Rab Q79L mutant. Expression of Rab5 
Q79L causes enlargement of early/late endosomes (Stenmark et al., 
1994), a strategy that has been used to interrogate the factors that 
regulate GPCR sorting into multivesicular endosomes (O’Keeffe 
et al., 2008; Henry et al., 2011; Dores et al., 2012b). Cells were then 
transfected with either nonspecific or ARRDC3 siRNAs. After 
with nonspecific or ARRDC3-siRNAs before stimulation with ago-
nist. Cells lacking ARRDC3 expression showed significantly less 
degradation of PAR1 after agonist incubation than nonspecific 
siRNA–transfected control cells (Figure 3A). These findings suggest 
FIGURE 2: ARRDC3 is required for PAR1 degradation. (A) FLAG-
PAR1–expressing HeLa cells were transfected with nonspecific (ns) or 
ALIX- or ARRDC3-specific siRNAs and then stimulated with 100 μM 
SFLLRN for 60 min. Cell lysates were collected, and the extent of 
PAR1 degradation was quantified by densitometry. The data 
represent the mean ± SD (n = 3) and were compared using two-way 
ANOVA (***p < 0.001). (B) PAR1-expressing HeLa cells were 
cotransfected with nonspecific (ns) or ARRDC3-specific siRNAs and 
either pcDNA vector or siRNA-resistant HA-ARRDC3 and then 
stimulated for 60 min with 100 μM SFLLRN. The amount of PAR1 
remaining was quantified by densitometry. The data represent the 
mean ± SD (n = 3) and were analyzed by two-way ANOVA 
(***p < 0.001, n = 3).
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Depletion of ARRDC3 disrupts ALIX 
binding to PAR1 and the ESCRT-III 
complex
The degradation of activated PAR1 requires 
binding to ALIX, which facilitates interaction 
between PAR1 and the ESCRT-III complex 
(Dores et al., 2012a). We next examined 
whether ARRDC3 is required for PAR1 inter-
action with ALIX. HeLa cells expressing 
FLAG-PAR1 were transfected with nonspe-
cific or ARRDC3 siRNAs and then stimulated 
with agonist. Cells were lysed and immuno-
precipitated with anti-FLAG antibody, and 
the coprecipitation of ALIX was assessed by 
immunoblot. In nonspecific siRNA–trans-
fected cells, endogenous ALIX coimmuno-
precipitated with activated PAR1 at 10 min 
(Figure 5A, lanes 2–4), whereas ARRDC3 
depletion significantly reduced ALIX inter-
action with activated PAR1 (Supplemental 
Figure S4A and Figure 5A, lanes 5–7). These 
results suggest that the loss of ARRDC3 dis-
rupts the capacity of ALIX to bind to acti-
vated PAR1. We next tested whether deple-
tion of ARRDC3 inhibits ALIX binding to the 
ESCRT-III subunit CHMP4B after PAR1 acti-
vation. ALIX binds to CHMP4B via its N-ter-
minal Bro1 domain (McCullough et al., 
2008), and ALIX is required for CHMP4B in-
teraction with activated PAR1 (Dores et al., 
2012a). PAR1-expressing HeLa cells were 
transfected with HA-CHMP4B and either 
nonspecific or ARRDC3 siRNAs and then in-
cubated with agonist. Cell lysates were im-
munoprecipitated with anti-HA (CHMP4B) 
antibody, and the coprecipitation of ALIX 
was assessed by immunoblot. In cells trans-
fected with nonspecific siRNA, activation of 
PAR1 increased endogenous ALIX coimmu-
noprecipitation with CHMP4B (Figure 5B, 
lanes 2 and 3). In contrast, ARRDC3 deple-
tion caused a slight increase in basal interac-
tion between ALIX and CHMP4B that was 
not statistically significant when compared 
with nonspecific samples (Supplemental 
Figure S4B and Figure 5B, lane 5). However, 
stimulation of PAR1 did not induce ALIX in-
teraction with CHMP4B in agonist-stimu-
lated cells lacking ARRDC3 (Figure 5B, lane 
6). These findings suggest that ARRDC3 regulates ALIX at the late 
endosome by facilitating ALIX interaction with both PAR1 and the 
ESCRT-III complex.
ARRDC3 mediates ALIX ubiquitination
ALIX becomes ubiquitinated during viral budding (Sette et al., 
2010), suggesting that ubiquitination may be important for ALIX 
function. However, ALIX ubiquitination in response to GPCR activa-
tion has not been previously examined. PAR1-expressing HeLa cells 
were transfected with HA-ALIX and incubated with agonist. ALIX 
was immunoprecipitated with anti-HA antibody, and ubiquitination 
was assessed by immunoblot using an anti-ubiquitin antibody. ALIX 
appears to be ubiquitinated under basal conditions (Figure 6A, lane 
transfections, cells were treated with 2 mM leupeptin to inhibit lyso-
somal degradation, incubated with anti-FLAG antibody at 4°C to la-
bel the PAR1 surface cohort, and stimulated with agonist. In nonspe-
cific siRNA–treated cells, PAR1 accumulation in the lumen of 
Rab5-positive endosomes was clearly evident after 60 min of stimu-
lation with agonist and was quantified by line-scan analysis (Figure 
4C), consistent with previous studies (Dores et al., 2012b). In con-
trast, activated PAR1 appears to localize at the limiting membrane of 
Rab5-positive endosomes and be excluded from the lumen of the 
endosomes in cells depleted of endogenous ARRDC3 (Figure 4C). 
Taken together, these findings suggest that ARRDC3 regulates PAR1 
sorting at late/multivesicular endosomes rather than early in the en-
docytic pathway.
FIGURE 3: ARRDC3 is required for the ubiquitin-independent degradation of PAR1. (A) HeLa 
cells expressing the FLAG-PAR1 0K mutant were transfected with nonspecific (ns) or ARRDC3 
siRNAs and then stimulated for 60 min with 100 μM SFLLRN. Cell lysates were analyzed by 
immunoblot. The amount of PAR1 0K remaining was quantified by densitometry. The data 
represent the mean ± SD (n = 3) and were compared by two-way ANOVA (**p < 0.01). 
(B) HeLa cells were transfected with nonspecific (ns) or ARRDC3-specific siRNAs and then 
treated with 10 nM EGF for 30 min. The amount of activated EGFR remaining was quantified, 
and the data represent the mean ± SD (n = 3). (C) HeLa cells expressing FLAG-PAR2 were 
transfected with nonspecific (ns) or ARRDC3 siRNAs and then stimulated with 100 μM SLIGKV 
for 120 min. The amount of activated PAR2 remaining was quantified, and the data represent 
mean ± SD (n = 3).
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stimulated ALIX ubiquitination. We trans-
fected FLAG-PAR1 HeLa cells with HA-ALIX 
and either nonspecific or ARRDC3 siRNAs 
and then treated them with agonist. Cells 
were lysed and immunoprecipitated with 
anti-HA antibody, and the ubiquitination of 
ALIX was determined. In cells treated with 
nonspecific siRNA, activation of PAR1 in-
duced ALIX ubiquitination (Supplemental 
Figure S5 and Figure 6B, lanes 2–4); how-
ever, cells depleted of ARRDC3 failed to ex-
hibit a significant increase in ALIX ubiquiti-
nation after agonist stimulation (Figure 6B, 
lanes 6–8). These results indicate that 
ARRDC3 is required for ALIX ubiquitination 
induced by activation of PAR1.
WWP2 E3 ubiquitin ligase mediates 
PAR1 degradation
We next sought to define the E3 ubiquitin 
ligase that mediates ALIX ubiquitination in-
duced by GPCR activation. ARRDC3 con-
tains two PPxY motifs within its C-terminus 
that bind to the WW domains of NEDD4-
family HECT domain–containing E3 ubiqui-
tin ligases, including atrophin1-interacting 
protein 4 (AIP4), WWP1, WWP2, NEDD4.1, 
and NEDD4.2 (Nabhan et al., 2010; Rauch 
and Martin-Serrano, 2011; Han et al., 2012; 
Shea et al., 2012). An siRNA screen of all 
nine NEDD4 family members was per-
formed to determine whether any of the 
NEDD4-family E3 ligases are required for 
PAR1 degradation, a receptor that does not 
require direct ubiquitination for lysosomal 
sorting (Dores et al., 2012a). FLAG-PAR1 
HeLa cells were transfected with nonspecific 
siRNAs, or siRNAs targeting each of the nine 
E3 ubiquitin ligases of the NEDD4 family. 
Transfection of siRNAs specific to the Smad 
ubiquitin regulatory factor 1 (SMURF1), 
SMURF2, NEDL1, NEDL2, AIP4, or WWP1 
E3 ligases reduced expression of the target 
mRNA but did not significantly inhibit ago-
nist-induced PAR1 degradation (Figure 7, A 
and D). Similarly, NEDD4.1 and NEDD4.2 
expression was reduced in siRNA-trans-
fected cells (Supplemental Figure S6A) but 
failed to affect activated PAR1 degradation 
compared with nonspecific siRNA–trans-
fected cells (Figure 7, B and D). In contrast, 
siRNA-mediated depletion of WWP2 
caused a marked inhibition of agonist-
driven PAR1 degradation, and only ∼15% of 
receptor was degraded after 60 min of ago-
nist incubation (Figures 7, C and D). PAR1 
expression at the cell surface was not affected in WWP2-depleted 
cells (Supplemental Figure S6B). Although ubiquitination of PAR1 is 
not required for lysosomal sorting (Dores et al., 2012a), the receptor 
is ubiquitinated after agonist stimulation (Wolfe et al., 2007; Chen 
et al., 2011). However, WWP2 depletion failed to affect agonist-in-
duced ubiquitination of PAR1 (Supplemental Figure S6C), suggesting 
2), consistent with previous findings (Sette et al., 2010, 2013). How-
ever, approximately threefold increase in ALIX ubiquitination was 
evident after 10 min of agonist stimulation (Figure 6A, lane 3), which 
returned to basal levels at 20 min (Figure 6A, lane 4). These results 
suggest that ALIX ubiquitination is a regulated response to GPCR 
activation. We next tested whether ARRDC3 is required for PAR1-
FIGURE 4: ARRDC3 is required for PAR1 sorting at late endosomes. (A) HeLa cells expressing 
FLAG-PAR1 were transfected with nonspecific (ns), ALIX, or ARRDC3 siRNA and then stimulated 
with 100 μM SFLLRN. The remaining surface PAR1 was measured by ELISA. The data represent 
the mean ± SD (n = 3). (B) HeLa cells expressing FLAG-PAR1 (red) were transfected with ns or 
ARRDC3 siRNA. Cells were stimulated with 100 μM SFLLRN and then fixed and stained with 
anti-EEA1 antibody (green). Insets show magnification of the boxed regions. Scale bars, 10 μm. 
The data (mean ± SD, n = 6) represent Pearson’s r calculated for PAR1 and EEA1 and were 
compared using Student’s t test (***p < 0.001). (C) ARRDC3 is required for PAR1 sorting into 
MVEs. FLAG-PAR1 HeLa cells were cotransfected with GFP-Rab5 Q79L and either ns or 
ARRDC3 siRNA. Cells were treated with leupeptin and then stimulated for 60 min with 100 μM 
SFLLRN. The data (mean ± SD, n = 6) represent the fluorescence intensity of PAR1 inside 
Rab5-positive endosomes as measured by line scan. The data were compared using Student’s 
t test (***p < 0.001).
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that WWP2 may modulate an important regulator of PAR1 lyso-
somal sorting rather than the receptor itself. These findings indicate 
that activated PAR1 lysosomal sorting is regulated by WWP2 E3 
ubiquitin ligase through a mechanism that does not appear to affect 
direct receptor ubiquitination.
WWP2 mediates ALIX ubiquitination
Previous studies proposed that α-arrestins recruit E3 ubiquitin li-
gases to ALIX during viral budding (Rauch and Martin-Serrano, 
2011); however, the NEDD4.1 E3 ligase has been shown to bind to 
and ubiquitinate ALIX (Sette et al., 2010). Because ARRDC3 is re-
quired for ALIX ubiquitination (Figure 6B), we examined whether 
ARRDC3 is required for ALIX interaction with WWP2. COS7 cells 
transfected with FLAG-WWP2 and either HA-ARRDC3 or HA-ALIX 
were lysed and immunoprecipitated with anti-FLAG antibody. Co-
precipitation of ARRDC3 with WWP2 was easily detected compared 
with immunoglobulin G (IgG) control (Figure 8A, lanes 1 and 2), con-
sistent with previous findings (Rauch and Martin-Serrano, 2011; 
Shea et al., 2012). We observed that expression of ARRDC3 caused 
a decrease in levels of WWP2 compared with ALIX (Supplemental 
Figure S7A), suggesting that ARRDC3 interaction with WWP2 might 
regulate WWP2 turnover. In contrast, WWP2 expression levels were 
higher when coexpressed with HA-ALIX, and ALIX failed to copre-
cipitate with FLAG-WWP2 (Figure 8A, lanes 3 and 4). Next we ex-
amined whether ectopic expression of ARRDC3 could facilitate 
WWP2 interaction with ALIX. COS7 cells coexpressing FLAG-WWP2 
and either HA-ARRDC3 wild type or HA-ARRDC3 R320Z, a trunca-
tion mutant that cannot bind to E3 ligases or ALIX (Rauch and 
Martin-Serrano, 2011), were immunoprecipitated with anti-FLAG 
antibody. As previously observed, WWP2 expression was reduced in 
cells expressing ARRDC3 WT but not the mutant ARRDC3 R320Z 
(Supplemental Figure S7B), leading to a reduction in immunopre-
cipitated WWP2 (Supplemental Figure S7C). In contrast, expression 
of either ARRDC3 WT or ARRDC3 R320Z did not significantly affect 
endogenous ALIX expression (Supplemental Figure S7B). ALIX co-
precipitated with WWP2 in cells expressing ARRDC3 wild type 
(Figure 8B, lane 3) but not in ARRDC3 R320Z–expressing cells 
(Figure 8B, lane 4). These results suggest that ARRDC3 mediates the 
interaction between WWP2 and ALIX and requires its C-terminal 
binding domain.
WWP2 mediates ALIX ubiquitination and binding to PAR1 
and the ESCRT-III complex
Next we assessed whether WWP2 is required for ALIX ubiquitina-
tion. We transfected PAR1-expressing HeLa cells with HA-ALIX and 
stimulated them with agonist. We then analyzed the ubiquitination 
status of ALIX by immunoblot using an anti-ubiquitin antibody. PAR1 
stimulation induced approximately threefold increase in ALIX ubiq-
uitination in cells transfected with nonspecific siRNA (Figure 9A, 
lanes 1–3). However, depletion of WWP2 resulted in significant at-
tenuation of ALIX ubiquitination (Figure 9A, lanes 4–6). These data 
indicate that WWP2 is required for ubiquitination of ALIX in re-
sponse to activation of PAR1. Because WWP2 is required for ALIX 
ubiquitination, we examined whether WWP2 depletion disrupts 
ALIX binding to PAR1. We transfected HeLa cells expressing FLAG-
PAR1 with nonspecific or ARRDC3 siRNAs and then treated them 
with agonist. We immunoprecipitated cell lysates with anti-FLAG 
antibody and assessed coprecipitation of endogenous ALIX by im-
munoblot. In nonspecific siRNA–transfected cells, ALIX coprecipi-
tated with activated PAR1 (Figure 9B, lane 3), whereas in cells de-
pleted of WWP2, ALIX interaction with PAR1 was markedly reduced 
(Figure 9B, lanes 5 and 6). These results suggest that WWP2 
FIGURE 5: ARRDC3 mediates ALIX interaction with PAR1 and the 
ESCRT-III complex. (A) HeLa cells expressing FLAG-PAR1 were 
transfected with nonspecific (ns) or ARRDC3 siRNA and then 
stimulated for the indicated times with 100 μM SFLLRN. FLAG-PAR1 
immunoprecipitates were probed with anti-ALIX antibody. ALIX 
precipitation was quantified by densitometry, and the data (mean ± 
SD, n = 3) were analyzed using two-way ANOVA (***p < 0.001; 
**p < 0.01). (B) HeLa cells expressing FLAG-PAR1 were cotransfected 
with HA-CHMP4B and either ns or ARRDC3 siRNA and then 
stimulated for the indicated times with 100 μM SFLLRN. HA-CHMP4B 
immunoprecipitates were probed with anti-ALIX antibody. ALIX 
precipitation was quantified by densitometry, and the data (mean ± 
SD, n = 3) were analyzed using two-way ANOVA (***p < 0.001).
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sorting mechanisms that regulate signaling receptors like GPCRs 
and other transmembrane proteins. However, little is known about 
the ALIX lysosomal pathway or how GPCR sorting through this path-
way is regulated. In this study, we describe a new mechanism for the 
regulation of ALIX-dependent GPCR lysosomal sorting that requires 
the α-arrestin ARRDC3. We show that ARRDC3 mediates the ubiq-
uitination of ALIX through the recruitment of the E3 ubiquitin ligase 
WWP2. These findings reveal a novel role for ARRDC3-mediated 
ubiquitination of ALIX in the lysosomal sorting of the GPCR PAR1.
The mammalian α-arrestins have emerged as adaptor proteins 
that may regulate endosomal sorting of GPCRs; however, their exact 
role remains controversial. Unlike β-arrestins, the α-arrestins (with 
the exception of ARRDC5) contain PPXY motifs that are bound by 
the WW-domains of NEDD4-family E3 ubiquitin ligases (Rauch and 
Martin-Serrano, 2011). Therefore the α-arrestins may function as 
adaptors for the recruitment of ubiquitination machinery to GPCRs. 
Initial reports suggested that ARRDC3 facilitates the ubiquitination 
and degradation of activated β2AR by mediating the recruitment of 
NEDD4-family E3 ubiquitin ligases (Nabhan et al., 2010). Subse-
quent studies demonstrated that multiple α-arrestins facilitate the 
ubiquitination of β2AR and the vasopressin 2 receptor (Shea et al., 
mediates ALIX binding to PAR1. We next determined whether 
WWP2 is required for ALIX interaction with CHMP4B. We trans-
fected HeLa cells expressing FLAG-PAR1 with HA-CHMP4B and ei-
ther nonspecific or ARRDC3 siRNAs, incubated them with agonist, 
and lysed them. ALIX coprecipitated with CHMP4B after agonist 
stimulation in nonspecific siRNA–treated cells (Figure 9C, lane 3). 
However, ALIX coprecipitation with CHMP4B was substantially re-
duced in cells deficient in WWP2 expression (Figure 9C, lanes 5 and 
6). The extent of ARRDC3 depletion was consistent throughout 
these experiments (Supplemental Figure S8). These results demon-
strate that WWP2 is required for ALIX binding to CHMP4B after ac-
tivation of PAR1. Taken together, these data indicate that ARRDC3 
coordinates the WWP2-dependent ubiquitination of ALIX after 
PAR1 activation, which appears to serve as a critical regulatory func-
tion in the lysosomal sorting of PAR1 (Figure 9D).
DISCUSSION
We previously discovered a novel lysosomal sorting pathway for GP-
CRs mediated by the adaptor protein ALIX that bypasses ubiquitin-
binding ESCRTs and receptor ubiquitination (Dores et al., 2012a). 
The ALIX lysosomal pathway illustrates the diversity of intracellular 
FIGURE 6: ARRDC3 mediates ALIX ubiquitination after PAR1 stimulation. (A) FLAG-PAR1 HeLa cells were transfected 
with HA-ALIX and then stimulated with 100 μM SFLLRN. Cell lysates were immunoprecipitated with anti-HA antibody 
and then analyzed by immunoblot with anti-ubiquitin antibodies. ALIX ubiquitination was quantified by densitometry, 
and the data (mean ± SD, n = 3) were analyzed using two-way ANOVA (**p < 0.01). (B) FLAG-PAR1 HeLa cells were 
transfected with HA-ALIX and either nonspecific (ns) or ARRDC3 siRNAs and then stimulated with 100 μM SFLLRN. Cell 
lysates were immunoprecipitated with anti-HA antibody and then analyzed by immunoblot with anti-ubiquitin 
antibodies. ALIX ubiquitination was quantified by densitometry, and the data (mean ± SD, n = 3) were analyzed using 
two-way ANOVA (***p < 0.001).
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β2AR lysosomal sorting (Han et al., 2012). Instead, α-arrestin–medi-
ated β2AR ubiquitination may regulate nonlysosomal endosomal 
trafficking that could modulate signaling or recycling. Our findings 
2012). However, these findings were challenged by the discovery 
that the β-arrestins primarily direct β2AR ubiquitination before lyso-
somal degradation and that depletion of ARRDC3 does not affect 
FIGURE 7: WWP2 is required for PAR1 degradation. (A–C) HeLa cells expressing FLAG-PAR1 were transfected with 
nonspecific (ns) siRNA or siRNAs targeting each of the nine human NEDD4-family HECT E3-ubiquitin ligases and then 
stimulated with 100 μM SFLLRN. Cell lysates were collected and analyzed by immunoblot. (A) mRNA from HeLa cells 
expressing FLAG-PAR1 transfected with siRNAs targeting AIP4, WWP1, SMURF1, SMURF2, NEDL1, and NEDL2 was 
PCR amplified using primers targeting the open reading frame of each ligase. The amount of amplified product was 
quantified by densitometry, and values represent the fraction of nonspecific control. (D) The extent of PAR1 degradation 
was measured by densitometry, and the data (mean ± SD, n = 3) were analyzed using two-way ANOVA (***p < 0.001).
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demonstrate that ARRDC3 is not required for the degradation of 
PAR2, a ubiquitinated GPCR that is sorted to the lysosome via the 
canonical ESCRT pathway (Hasdemir et al., 2007), suggesting that 
ARRDC3 is not required for the lysosomal sorting of ubiquitinated 
GPCRs. Our results support a mechanism by which ARRDC3 regu-
lates GPCR lysosomal sorting by mediating the ubiquitination of the 
adaptor protein ALIX and not the receptor.
Recent studies have uncovered the role of ubiquitination in the 
regulation of adaptor proteins that facilitate the multivesicular endo-
somal sorting of mammalian GPCRs. The ESCRT-0 subunit HRS is a 
critical adaptor protein that binds to ubiquitinated GPCRs such as 
CXCR4, a GPCR for the chemokine SDF-1 (Marchese et al., 2003). 
HRS becomes ubiquitinated after CXCR4 activation, a process that 
is required for sorting of CXCR4 into multivesicular endosomes 
(Malik and Marchese, 2010; Sierra et al., 2010). Of interest, β–arres-
tin-1 recruits the NEDD4-family E3 ubiquitin ligase AIP4 to late en-
dosomes (Bhandari et al., 2007), facilitating the ubiquitination of 
HRS (Malik and Marchese, 2010). HRS ubiquitination stabilizes inter-
action with the ESCRT-I complex subunit TSG101 (Malik and 
Marchese, 2010). These studies represent the first evidence that β-
arrestin–dependent ubiquitination of adaptor proteins regulates 
membrane trafficking of GPCRs.
Here we report a novel role for the α-arrestin ARRDC3 in facili-
tating ubiquitination of ALIX during activated GPCR lysosomal sort-
ing. We demonstrate that ARRDC3 is essential for PAR1 lysosomal 
sorting and that depletion of endogenous ARRDC3 inhibits ALIX 
binding to PAR1 and to the ESCRT-III subunit CHMP4B. We also 
found that ARRDC3 is required for ALIX ubiquitination in response 
to activation of PAR1. We observed that the pattern of ALIX ubiqui-
tination varies slightly but always includes monoubiquitinated and 
polyubiquitinated forms that are sensitive to ARRDC3 depletion. 
Future studies will focus on the function of ALIX monoubiquitination 
and polyubiquitination in the regulation of ALIX. Ubiquitination of 
ALIX has also been observed during the budding of viruses from the 
plasma membrane (Sette et al., 2010), a process that requires ES-
CRTs and ALIX to package viral particles into membrane buds. 
ARRDC3 facilitates ALIX ubiquitination during viral budding, and 
ALIX ubiquitination is required for viral particle release (Rauch and 
Martin-Serrano, 2011). These findings suggest that ubiquitination 
regulates ALIX function during the packaging of cargo at the plasma 
membrane and at the late endosome.
Ubiquitin may regulate ALIX by facilitating ALIX dimerization. 
ALIX harbors a highly conserved ubiquitin-binding domain (Keren-
Kaplan et al., 2013; Pashkova et al., 2013) that is required for ALIX 
dimerization in vitro (Keren-Kaplan et al., 2013). ALIX dimerization 
mediates interaction with ESCRT-III filaments that form on mem-
branes during viral budding (Pires et al., 2009), and disruption of 
ALIX dimerization inhibits the release of HIV (Pires et al., 2009; Bissig 
et al., 2013). ALIX dimers colocalize with internalized PAR1 and 
ARRDC3 (Figure 1C), and our findings suggest that ALIX ubiquitina-
tion is required for the lysosomal sorting of PAR1. Future studies will 
interrogate the function of ARRDC3 and WWP2 in regulating ALIX 
dimerization during GPCR sorting and will investigate the function 
of the ALIX ubiquitin-binding domain in the trafficking of GPCRs.
FIGURE 8: ARRDC3 mediates WWP2 interaction with ALIX. (A) COS7 
cells were cotransfected with FLAG-WWP2 and either HA-ARRDC3 or 
HA-ALIX. Cell lysates were immunoprecipitated with anti-HA or IgG 
control antibodies, and precipitates were analyzed by immunoblot 
with anti-FLAG antibodies. (B) COS7 cells were cotransfected with 
FLAG-WWP2 and either HA-ARRDC3 WT or HA-ARRDC3 R320Z. Cell 
lysates were immunoprecipitated with anti-FLAG antibody, and 
precipitates were analyzed by immunoblot with anti-ALIX antibodies. 
Endogenous ALIX coprecipitation was quantified by densitometry, 
and the data (mean ± SD, n = 3) were analyzed using Student’s t test 
(**p < 0.01).
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FIGURE 9: WWP2 mediates ALIX ubiquitination and binding to PAR1 and CHMP4B. (A) PAR1 HeLa cells were 
transfected with HA-ALIX and either nonspecific (ns) or WWP2 siRNAs and then stimulated for the indicated times with 
100 μM SFLLRN. Cell lysates were immunoprecipitated with anti-HA antibody. ALIX ubiquitination was quantified by 
densitometry, and the data (mean ± SD, n = 3) were analyzed using two-way ANOVA (**p < 0.01). (B) HeLa cells 
expressing FLAG-PAR1 were cotransfected with either nonspecific (ns) or WWP2 siRNAs and then stimulated with 
100 μM SFLLRN. Cell lysates were immunoprecipitated with anti-FLAG antibody. ALIX coprecipitation was quantified by 
densitometry, and the data (mean ± SD, n = 3) were analyzed using two-way ANOVA (***p < 0.001). (C) HeLa cells 
expressing FLAG-PAR1 were cotransfected with HA-CHMP4B and either nonspecific (ns) or WWP2 siRNAs and then 
stimulated for the indicated times with 100 μM SFLLRN. Cell lysates were immunoprecipitated with anti-HA antibody. 
ALIX coprecipitation was quantified by densitometry, and the data (mean ± SD, n = 3) were analyzed using two-way 
ANOVA (***p < 0.001). (D) Model of ARRDC3-mediated ALIX ubiquitination and PAR1 sorting at the MVE.
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Plasmids and cell lines
The full-length human N-terminal, FLAG-tagged PAR1 WT, FLAG-
PAR1 0K, and FLAG-PAR2 WT cDNAs cloned into the mammalian 
expression vector pBJ were described previously (Trejo et al., 
2000; Wolfe et al., 2007; Ricks and Trejo, 2009). The PAR1-YFP 
cDNA and ARRDC3-RLuc cDNA construct were cloned into the 
pcDNA3.1 vector for this study. The HA-ARRDC3 WT cDNA 
cloned into the pcDNA3.1 vector was provided by Q. Lu (Harvard 
University, Cambridge, MA). The HA-ALIX WT cDNA cloned into 
the pcDNA3.1 vector was provided by J. Martin-Serrano (King’s 
College, London, United Kingdom). The GFP-Rab5 WT and GFP-
Rab5 Q79L cDNAs were provided by A. Marchese (Loyola Univer-
sity, Maywood, IL). The split-YFP ALIX-ΔPRD plasmids were pro-
vided by J. Gruenberg (University of Geneva, Geneva, 
Switzerland). HeLa cells stably expressing FLAG-PAR1, FLAG-
PAR1 0K, or FLAG-PAR2 cloned into pBJ vectors were generated 
by cotransfection with a plasmid encoding a hygromycin-resis-
tance gene, selected in 250 μg/ml hygromycin, and screened by 
cell surface ELISA (Trejo et al., 2000). COS-7 cells were transiently 
transfected with PAR1-YFP and/or ARRDC3-Rluc plasmids for 
BRET analysis. COS-7 cells were cotransfected with FLAG-WWP2 
and either HA-ARRDC3 or HA-ALIX for coimmunoprecipitation 
studies.
siRNA and cDNA transfections
HeLa cells were transfected with plasmid DNA using 1 mg/ml poly-
ethylenimine (PEI) at a 6:1 ratio (6 μl PEI:1 μg plasmid). siRNA trans-
fection was performed using Oligofectamine (Invitrogen) per manu-
facturer’s instructions. All single siRNAs were purchased from Qiagen 
or Invitrogen: nonspecific, 5′-GGCTACGTCCAGGAGCGCACC-3′; 
ALIX #1, 5′-AAGTACCTCAGTCTATATTGA-3′; ALIX #3, 5′-AATC-
GAGACGCTCCTGAGATA-3′; ARRDC3, 5′-AAGGGAAAATGAA-
GG AAGTAA-3′; NEDD4.1, 5′-CCGGAGAATTATGGGTGTCAA-3′; 
NEDD4.2, 5′-AAGATCATAACACAAAGACTA-3′; WWP1, 5′-AAGAA-
GTCATCTGTAACTAAA-3′; WWP2, 5′-TAGACACGTCCGTTGGG-
CAGCTCTC-3′; SMURF1, 5′-GCATCGAAGTGTCCAGAGAAG-3′; 
SMURF2, 5′-CCGGATCTTCACAACAGTTTA-3′; NEDL1, 5′-AAGAT-
GAGGTCTTGTCCGAAA-3′; and NEDL2, 5′-AAGTGGGTACCTC-
CAGTTTAA-3′. SMARTpool siRNAs were purchased from Dharma-
con: AIP4, 5′-GGTGACAAAGAGCCAACAGAG-3′.
Reverse transcriptase-PCR 
The first-strand cDNA was generated from mRNA extracted from 
either HeLa using SuperScript II Reverse Transcriptase (Invitrogen) 
following the manufacturer’s instructions. The reverse transcriptase 
enzyme was omitted from the cDNA synthesis reaction in the con-
trol samples. The first-strand cDNA was amplified via PCR using 
primer pairs specific for SMURF1, forward, 5′-GCCTGTACTGGAC-
CACACCT-3′, and reverse, 5′-TGAGCTCATTGAACCCCTTC-3′; 
SMURF2, forward, 5′-ATGGTTCTGGAAAGCTGTGG-3′, and reverse, 
5′-TTCGATTGAAGCAAGTGTGG-3′; NEDL1, forward, 5′-GTTTT-
GTGTCCTTGCCCACT-3′, and reverse, 5′-GAATTGCAGCTGTC-
CACTCA-3′; NEDL2, forward, 5′-GACCGAGTCTCTCGATCAGG-3′, 
and reverse, 5′-AAGAGAGGAGCACCGTGTGT-3′; and AIP4, for-
ward, 5′-GTTGGGAGCAGAGAGTGGAC-3′, and reverse, 5′-TCA-
TAGTTCCGGACGGATTC-3′. The PCR amplification products were 
resolved by 1.8% (wt/vol) agarose gel electrophoresis and visualized 
by ethidium bromide staining.
Bioluminescence resonance energy transfer 
COS-7 cells were transfected with 0.1 μg of ARRDC3-Rluc and a 
range (0–1.0 μg) of PAR1-YFP for 48 h, detached with Cellstripper 
ARRDC3 mediates the ubiquitination of ALIX through the recruit-
ment of NEDD4-family E3 ubiquitin ligases. Because ARRDC3 can 
interact with multiple NEDD4-family E3 ligases (Rauch and Martin-
Serrano, 2011; Han et al., 2012; Shea et al., 2012), we screened all 
nine human NEDD4-family E3 ligases for their function in PAR1 deg-
radation. Although depletion of SMURF1 and SMURF2 increased 
the basal levels of surface PAR1, it did not effect agonist-induced 
receptor degradation. However, depletion of WWP2 alone was suf-
ficient to block agonist-induced PAR1 degradation. Of importance, 
WWP2 is required for ALIX ubiquitination in response to PAR1 stim-
ulation. Although some reports suggested that ALIX can interact 
directly with NEDD4.1 (Sette et al., 2010), we observed that ARRDC3 
facilitates the interaction between ALIX and WWP2. Similarly to 
ARRDC3, WWP2 depletion also blocks ALIX binding to PAR1 and 
CHMP4B. In contrast, during viral budding, ARRDC3 recruits 
NEDD4.1 to ubiquitinate ALIX and mediates the recruitment of ES-
CRTs (Rauch and Martin-Serrano, 2011). Thus ARRDC3 appears to 
mediate ALIX ubiquitination through multiple E3 ubiquitin ligases in 
a context-dependent manner. In addition, ARRDC3 WT overexpres-
sion appears to reduce the expression of WWP2 in comparison to 
cells expressing a mutant of ARRDC3 lacking its C-terminus. How-
ever, overexpression of ARRDC3 WT does not appear to affect the 
expression of other E3 ligases, such as NEDD4.1 (Nabhan et al., 
2010). It will be important to determine the factors that may influ-
ence ARRDC3 recruitment and regulation of different E3 ubiquitin 
ligases in order to facilitate ALIX ubiquitination.
In summary, our study has revealed a novel mechanism for the 
regulation of ALIX-dependent GPCR lysosomal sorting by the α-
arrestin ARRDC3. Our results support a model in which ARRDC3 
recruits the NEDD4-family E3 ubiquitin ligase WWP2 to PAR1 at late 
endosomes to ubiquitinate ALIX, facilitating the sorting of PAR1 into 
intraluminal vesicles of MVE’s (Figure 9D). However, the mecha-
nisms that regulate ARRDC3 and WWP2 after activation of PAR1 
signaling are unclear. Recent work demonstrated that the NEDD4-
family E3 ligase AIP4 is itself ubiquitinated and regulated by a 
RING-E3 ligase, Deltex3L in response to CXCR4 activation 
(Holleman and Marchese, 2014). However, the signaling effectors 
that regulate Deltex3L activity are not known. It is unclear whether 
phosphorylation or ubiquitination regulates ARRDC3 and WWP2 
activity after PAR1 stimulation. Thus further studies are required to 
link GPCR signaling to ARRDC3- and WWP2-mediated ALIX ubiqui-
tination at late endosomes.
MATERIALS AND METHODS
Antibodies and reagents
PAR1 peptide agonist (SFLLRN) and PAR2 peptide agonist (SLIGKV) 
were synthesized and purified by reverse-phase, high-pressure liq-
uid chromatography at the Tufts University Core Facility (Boston, 
MA). Epidermal growth factor was purchased from Sigma-Aldrich 
(St. Louis, MO). Polyclonal anti-FLAG and anti-HA antibodies were 
purchased from Rockland Immunochemicals (Pottstown, PA). Anti-
EEA1 antibody was obtained from BD Biosciences (East Rutherford, 
NJ). Monoclonal anti-PAR1 WEDE antibody was purchased from 
Beckman Coulter (Brea, CA). Polyclonal anti-ARRDC3, monoclonal 
anti-ALIX, and monoclonal anti-Ub (P4D1) antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-EGFR 
antibody was obtained from Cell Signaling Technologies (Boston, 
MA). Monoclonal anti-HA antibody was purchased from Covance 
(San Diego, CA). Horseradish peroxidase–conjugated goat anti-rab-
bit and goat anti-mouse antibodies were purchased from Bio-Rad 
Laboratories (Hercules, CA). Alexa Fluor 488, 594, and 647 second-
ary antibodies were purchased from Invitrogen (Carlsbad, CA).
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(Mediatech, Manassas, VA), washed three times with phosphate-
buffered saline (PBS), and resuspended in PBS containing 0.5 mM 
MgCl2 and 0.1% glucose at a density of 5 × 105 cells/ml. Cells (90 μl) 
were added to a 96-well microplate in triplicate, and 10 μl of coelen-
terazine h substrate was added (final concentration, 5 μM). After an 
8-min delay, signals were determined with a TriStar LB 941 plate 
reader (Berthold Biotechnologies) using two filter settings at 480 and 
535 nm and MicroWIN 2000 software (Berthold Technologies, Oak 
Ridge, TN). The YFP signal was determined by exciting at 485 nm 
and detecting at 535 nm. Total luminescence was measured by inte-
grating the signal for 1 s/well without filter selection. Net BRET was 
calculated as previously described (Lin and Trejo, 2013). Data from 
three independent experiments were pooled and fitted with nonlin-
ear regression using Prism software (GraphPad, San Diego, CA).
PAR1 degradation assays
HeLa cells stably transfected with FLAG-PAR1 WT, FLAG-PAR1 0K, 
or FLAG-PAR2 WT were plated in 12-well plates (0.75 × 105 cells/
well) and grown overnight at 37°C. Cells were transfected with 
siRNA. For siRNA knockdown-rescue experiments, cells were first 
transfected with plasmids and then siRNA after an overnight incu-
bation. After 48 h, cells were washed and then incubated with or 
without 100 μM SFLLRN (PAR1) or 100 μM SLIGKV (PAR2) at 37°C 
for the indicated times. Cells were then placed on ice, washed with 
PBS, and lysed in Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.4, 
100 mM NaCl, 5 mM EDTA, 50 mM NaF, 10 mM sodium pyrophos-
phate, and 1% [vol/vol] Triton X-100) supplemented with protease 
inhibitors. Cell lysates were collected and sonicated for 10 s at 10% 
amplitude (Branson Model 450 sonifier), and protein concentration 
was normalized after quantification by bicinchoninic acid assay 
(Thermo Fisher Scientific, Waltham, MA). Equivalent amounts of ly-
sates were used for analysis by immunoblotting.
Immunoprecipitation
HeLa cells stably expressing FLAG-PAR1 WT were grown in six-well 
plates (2.0 × 105 cells/well) overnight at 37°C and then transfected 
with either HA-ALIX or HA-CHMP4B plasmid. Cells were incubated 
for 48 h, washed, and then stimulated for the indicated times with 
100 μM SFLLRN. For coimmunoprecipitations: Cells were washed 
and then lysed with NP-40 buffer (0.5% [vol/vol] NP40, 20 mM Tris-
HCl, pH 7.4, 150 mM NaCl) supplemented with protease inhibitors 
and 3 mg/ml N-ethylmaleimide (NEM). For ubiquitination assays, 
cells were washed and then lysed with RIPA buffer (5 mM EDTA, 
50 mM Tris-HCl, pH 8.0, 0.5% [wt/vol] Na deoxycholate, 1% [vol/vol] 
NP-40, 0.1% [wt/vol], 1% SDS) supplemented with protease inhibi-
tors and 3 mg/ml NEM or 10 μM PR-619 (Boston Biochem, Boston, 
MA). Lysates were sonicated for 10 s at 10% amplitude and then 
clarified by centrifugation at 14,000 rpm for 30 min at 4°C. Clarified 
lysates were incubated with protein A–Sepharose beads (GE Health-
care, Pittsburgh, PA) and the indicated antibodies overnight at 4°C. 
Beads were washed and resuspended in 2× Laemmli sample buffer. 
Immunoprecipitates were resolved on 6% SDS–PAGE gels to sepa-
rate higher–molecular weight ubiquitinated ALIX from unmodified 
ALIX and then transferred onto polyvinylidene fluoride and immu-
noblotted using anti-ubiquitin antibody.
Immunofluorescence microscopy
HeLa cells stably expressing FLAG-PAR1 WT were plated on cover-
slips in 12-well plates (0.75 × 105 cells/well) and incubated overnight 
at 37°C. Cells were transfected with the indicated plasmids and then 
incubated for 48 h. For the indicated experiments, cells were pre-
treated with 2 mM leupeptin for 1 h at 37°C to inhibit lysosomal 
degradation. Cells were washed and then labeled with anti-FLAG 
antibody at 4°C for 1 h to track the surface cohort of receptor. Cells 
were washed and then stimulated with 100 μM SFLLRN for the indi-
cated times. Cells were fixed in 4% paraformaldehyde, permeabi-
lized in 100% methanol, and treated with the indicated primary and 
secondary antibodies. Coverslips were mounted using Fluorsave 
reagent (EMD Biochemical, Billerica, MA). Images were acquired 
with a spinning-disk confocal system (Olympus, Waltham, MA) con-
figured with a microscope (IX81; Olympus) fitted with a PlanApo 60× 
oil objective (1.4 numerical aperture; Olympus) and a digital camera 
(ORCA-ER; Hamamatsu Photonics, San Diego, CA). Fluorescence 
images of 0.28-μm-thick XY-sections were acquired at room tem-
perature using SlideBook 5.0 software (Intelligent Imaging Innova-
tions, Denver, CO). Values of Pearson’s r for quantifying colocaliza-
tion were calculated from at least six independent cells from multiple 
experiments using SlideBook 5.0.
Statistics
Data were analyzed using Prism software (version 4.0; GraphPad 
Software). Statistical analysis was determined, as indicated, by per-
forming either Student’s t test or two-way analysis of variance 
(ANOVA).
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